Cargando…

Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis

An association among the use of angiotensin converting enzyme (ACE) inhibitors and angiotensin‐receptor blockers (ARBs) with the clinical outcomes of coronavirus disease 2019 (COVID‐19) is unclear. PubMed, EMBASE, MedRxiv, and BioRxiv were searched for relevant studies that assessed the association...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiao, Long, Chuyan, Xiong, Qinmei, Chen, Chen, Ma, Jianyong, Su, Yuhao, Hong, Kui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436520/
https://www.ncbi.nlm.nih.gov/pubmed/32757246
http://dx.doi.org/10.1002/clc.23421
_version_ 1783572531520733184
author Liu, Xiao
Long, Chuyan
Xiong, Qinmei
Chen, Chen
Ma, Jianyong
Su, Yuhao
Hong, Kui
author_facet Liu, Xiao
Long, Chuyan
Xiong, Qinmei
Chen, Chen
Ma, Jianyong
Su, Yuhao
Hong, Kui
author_sort Liu, Xiao
collection PubMed
description An association among the use of angiotensin converting enzyme (ACE) inhibitors and angiotensin‐receptor blockers (ARBs) with the clinical outcomes of coronavirus disease 2019 (COVID‐19) is unclear. PubMed, EMBASE, MedRxiv, and BioRxiv were searched for relevant studies that assessed the association between application of ACEI/ARB and risk of COVID‐19, inflammation level, severity COVID‐19 infection, and death in patients with COVID‐19. Eleven studies were included with 33 483 patients. ACEI/ARB therapy might be associated with the reduced inflammatory factor (interleukin‐6) and elevated immune cells counts (CD3, CD8). Meta‐analysis showed no significant increase in the risk of COVID‐19 infection (odds ratio [OR]: 0.95, 95%CI: 0.89‐1.05) in patients receiving ACEI/ARB therapy, and ACEI/ARB therapy was associated with a decreased risk of severe COVID‐19 (OR: 0.75, 95%CI: 0.59‐0.96) and mortality (OR: 0.52, 95%CI: 0.35‐0.79). Subgroup analyses showed among the general population, ACEI/ARB therapy was associated with reduced severe COVID‐19 infection (OR: 0.79, 95%CI: 0.60‐1.05) and all‐cause mortality (OR: 0.31, 95%CI: 0.13‐0.75), and COVID‐19 infection (OR: 0.85, 95% CI: 0.66‐1.08) were not increased. Among patients with hypertension, the use of an ACEI/ARB was associated with a lower severity of COVID‐19 (OR: 0.73, 95%CI: 0.51‐1.03) and lower mortality (OR: 0.57, 95%CI: 0.37‐0.87), without evidence of an increased risk of COVID‐19 infection (OR: 1.00). On the basis of the available evidence, ACEI/ARB therapy should be continued in patients who are at risk for, or have COVID‐19, either in general population or hypertension patients. Our results need to be interpreted with caution considering the potential for residual confounders, and more well‐designed studies that control the clinical confounders are necessary to confirm our findings.
format Online
Article
Text
id pubmed-7436520
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wiley Periodicals, Inc.
record_format MEDLINE/PubMed
spelling pubmed-74365202020-08-19 Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis Liu, Xiao Long, Chuyan Xiong, Qinmei Chen, Chen Ma, Jianyong Su, Yuhao Hong, Kui Clin Cardiol Reviews An association among the use of angiotensin converting enzyme (ACE) inhibitors and angiotensin‐receptor blockers (ARBs) with the clinical outcomes of coronavirus disease 2019 (COVID‐19) is unclear. PubMed, EMBASE, MedRxiv, and BioRxiv were searched for relevant studies that assessed the association between application of ACEI/ARB and risk of COVID‐19, inflammation level, severity COVID‐19 infection, and death in patients with COVID‐19. Eleven studies were included with 33 483 patients. ACEI/ARB therapy might be associated with the reduced inflammatory factor (interleukin‐6) and elevated immune cells counts (CD3, CD8). Meta‐analysis showed no significant increase in the risk of COVID‐19 infection (odds ratio [OR]: 0.95, 95%CI: 0.89‐1.05) in patients receiving ACEI/ARB therapy, and ACEI/ARB therapy was associated with a decreased risk of severe COVID‐19 (OR: 0.75, 95%CI: 0.59‐0.96) and mortality (OR: 0.52, 95%CI: 0.35‐0.79). Subgroup analyses showed among the general population, ACEI/ARB therapy was associated with reduced severe COVID‐19 infection (OR: 0.79, 95%CI: 0.60‐1.05) and all‐cause mortality (OR: 0.31, 95%CI: 0.13‐0.75), and COVID‐19 infection (OR: 0.85, 95% CI: 0.66‐1.08) were not increased. Among patients with hypertension, the use of an ACEI/ARB was associated with a lower severity of COVID‐19 (OR: 0.73, 95%CI: 0.51‐1.03) and lower mortality (OR: 0.57, 95%CI: 0.37‐0.87), without evidence of an increased risk of COVID‐19 infection (OR: 1.00). On the basis of the available evidence, ACEI/ARB therapy should be continued in patients who are at risk for, or have COVID‐19, either in general population or hypertension patients. Our results need to be interpreted with caution considering the potential for residual confounders, and more well‐designed studies that control the clinical confounders are necessary to confirm our findings. Wiley Periodicals, Inc. 2020-08-05 /pmc/articles/PMC7436520/ /pubmed/32757246 http://dx.doi.org/10.1002/clc.23421 Text en © 2020 The Authors. Clinical Cardiology published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Liu, Xiao
Long, Chuyan
Xiong, Qinmei
Chen, Chen
Ma, Jianyong
Su, Yuhao
Hong, Kui
Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis
title Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis
title_full Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis
title_fullStr Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis
title_full_unstemmed Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis
title_short Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis
title_sort association of angiotensin converting enzyme inhibitors and angiotensin ii receptor blockers with risk of covid‐19, inflammation level, severity, and death in patients with covid‐19: a rapid systematic review and meta‐analysis
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436520/
https://www.ncbi.nlm.nih.gov/pubmed/32757246
http://dx.doi.org/10.1002/clc.23421
work_keys_str_mv AT liuxiao associationofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockerswithriskofcovid19inflammationlevelseverityanddeathinpatientswithcovid19arapidsystematicreviewandmetaanalysis
AT longchuyan associationofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockerswithriskofcovid19inflammationlevelseverityanddeathinpatientswithcovid19arapidsystematicreviewandmetaanalysis
AT xiongqinmei associationofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockerswithriskofcovid19inflammationlevelseverityanddeathinpatientswithcovid19arapidsystematicreviewandmetaanalysis
AT chenchen associationofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockerswithriskofcovid19inflammationlevelseverityanddeathinpatientswithcovid19arapidsystematicreviewandmetaanalysis
AT majianyong associationofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockerswithriskofcovid19inflammationlevelseverityanddeathinpatientswithcovid19arapidsystematicreviewandmetaanalysis
AT suyuhao associationofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockerswithriskofcovid19inflammationlevelseverityanddeathinpatientswithcovid19arapidsystematicreviewandmetaanalysis
AT hongkui associationofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockerswithriskofcovid19inflammationlevelseverityanddeathinpatientswithcovid19arapidsystematicreviewandmetaanalysis